These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 19009673)

  • 1. Tibolone in older postmenopausal women.
    Serati M; Uccella S; Bolis P
    N Engl J Med; 2008 Nov; 359(20):2173; author reply 2173. PubMed ID: 19009673
    [No Abstract]   [Full Text] [Related]  

  • 2. Tibolone in older postmenopausal women.
    Chlebowski RT; Prentice R
    N Engl J Med; 2008 Nov; 359(20):2172-3; author reply 2173. PubMed ID: 19005202
    [No Abstract]   [Full Text] [Related]  

  • 3. Tibolone and stroke.
    Prescrire Int; 2006 Jun; 15(83):107. PubMed ID: 16767815
    [No Abstract]   [Full Text] [Related]  

  • 4. Tibolone and the promise of ideal hormone-replacement therapy.
    El-Hajj Fuleihan G
    N Engl J Med; 2008 Aug; 359(7):753-5. PubMed ID: 18703480
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of tibolone on audiologic functions in menopausal women.
    Köşüş N; Köşüş A; Turhan NÖ; Kurtaran H
    Climacteric; 2011 Apr; 14(2):262-7. PubMed ID: 20690865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tibolone: the way to beat many a postmenopausal ailments.
    Lazovic G; Radivojevic U; Marinkovic J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.
    Kenemans P
    Gynecol Endocrinol; 2010 Apr; 26(4):237-9. PubMed ID: 20017707
    [No Abstract]   [Full Text] [Related]  

  • 8. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
    Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin expression in cervical epithelial cells of postmenopausal women: association with hormone therapy, tibolone, and raloxifene.
    Sioulas V; Christodoulakos G; Lambrinoudaki I; Politi E; Sergentanis TN; Creatsas G
    Fertil Steril; 2008 Apr; 89(4):1018-20. PubMed ID: 17689538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of efficacy of combined use of liquid cytology and immunohistochemical assay of p16ink4 and standard procedure and high risk evaluation by polymerase chain reaction of human papillomavirus infection in diagnosing cervical dysplasia and carcinoma].
    Raskin GA; Petrov SV; Orlova RV; Mal'tseva LI; Akhmetzianova AV; Farrakhova LN; Khasanov RSh
    Vopr Onkol; 2009; 55(2):192-5. PubMed ID: 19514374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical polyps in postmenopausal women: is there a difference in risk?
    Schnatz PF; Ricci S; O'Sullivan DM
    Menopause; 2009; 16(3):524-8. PubMed ID: 19179926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
    Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC;
    Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women.
    Sezer Ozer K; Erenus M; Yoldemir T
    Climacteric; 2009 Feb; 12(1):66-71. PubMed ID: 19012050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tibolone is not aromatized in postmenopausal women.
    Kloosterboer HJ
    Climacteric; 2008 Apr; 11(2):175; author reply 175-6. PubMed ID: 18365860
    [No Abstract]   [Full Text] [Related]  

  • 15. Cervical cancer risk factors and predictors of cervical dysplasia among women in south-west Nigeria.
    Ogunbowale T; Lawoyin TO
    Aust J Rural Health; 2008 Dec; 16(6):338-42. PubMed ID: 19032205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
    Carranza Lira S
    Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mass measurement and factors associated with risk of fracture in a group of peri- and postmenoupausal women.
    Rasheed A; Khurshid R; Aftab L
    J Ayub Med Coll Abbottabad; 2008; 20(1):48-51. PubMed ID: 19024185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
    Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
    Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of infection with high-risk human papillomavirus in women in Colombia.
    Soto-De Leon SC; Camargo M; Sanchez R; Leon S; Urquiza M; Acosta J; Monsalve D; Rodriguez LE; Patarroyo ME; Patarroyo MA
    Clin Microbiol Infect; 2009 Jan; 15(1):100-2. PubMed ID: 19154481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.